Biotech Companies


ADEPTRIXC81a- Rev. png
















Cell Assay Innovations






GlobalBio, Inc.





Epathochhem Logo 1.2











































Seqwell logo. jpg










Developing the next generation of bead-based bioassays, which employ mass spectrometry and optical imaging to facilitate high information content proteomic research.

Vladislav Bergo, CEO  



Developing advanced neuorostimulation products and neuromodulation technologies that reduce device failure rates and improved efficacy over time.

Larry Derose, CEO;  Barry Yomtov, CTO


Cellanyx Diagnostics LLC

Developing in vitro tissue and cell culturing techniques for use in research and in vitro diagnostics, specifically prognostic information for prostate cancer treatment decisions.

Ashok Chander,CEO; Mani Foroohar,CSO


Cell Assay Innovations, Inc.

A biotechnology service company dedicated to cell-based assay technology development with a focus on proprietary kinase assay panels for drug screening and other cell culture services.

Deborah Moshinsky, President; LiPing Wu, CSO


GlobalBio, Inc.

An antibody engineering company developing faster and more efficient methods for the discovery and optimization of antibodies for therapeutic settings.

Juan Carlos Almagro, PhD, Founder



Offers pharmaceutical and biotech companies reliable and efficient access to small molecule metabolites in order to accelerate drug R&D and reduce costs.

Marc Bazin, President; Ryan Buzdygon, Director of Operations



Developing  a neurostimulator device to mitigate insomnia.

Peter Kelley, Founder; John Douglas, Consultant


IVIVA Medical, Inc. (website under construction)

Developing bioengineered autologous dialysis grafts, an “implantable artificial kindney,” to substitute for, augment, or replace human kidney function without hemodialysis or the need for immunosuspression.

Harold Ott, MD, President & CEO; Charles Klassen, Research Scientist


Lariat Biosciences (website under construction)

Developing a non‐invasive diagnostic to detect early signs of cancer based on circulating DNA fragments arising from the death of tumor cells which carry the mutant genetic signature that gave rise to the abnormal growth.

Jonathan Larson, CEO


Lighthouse Proteomics, LLC

Lighthouse Proteomics offers advanced proteomic services and expertise to identify, characterize, and quantify proteins to support research and development for the biotech and pharmaceutical industry and academia.

Jeff Silva, CEO; Manor Askenazi, Director of Informatics


MCC Global Laboratories, Inc.

Develops, manufactures, and distributes innovative surface biological decontamination technology to a worldwide healthcare, life sciences, and biodefense market.

Loutfi Kachou, Dan Bandar, Gina Bandar-Kachou


MiMecore Therapeutics LLC

Developing a novel suite of engineered proteoglycan-mimics designed to assist in the healing and restoration of soft tissue extracellular matrix compromised by age, injury or medical disorder.

Vince Novak, CEO & Founder; Gene Skrabut, VP Research; Tom Jozefiak, VP Science & Technology



RAN Biotechnologies, Inc.

Designs and manufacture two types of materials: (1) Solid Resins for selective capture and controlled release of viruses, bacteria, and proteins. Examples of related applications are viral clearance, vaccine purification, fluid disinfection and diagnostics; (2) FluoroSurfactants for droplet microfluidics.

Roger Nassar, CEO



seqWell, Inc.

Offers a DNA sequencing service called kiloSEQ ™, based on novel and proprietary technology that will enable high-quality, long-read sequencing of plasmids and amplicons for development of therapeutic biologicals and synthetic biology applications.

Joseph Mellor, CEO; Jack Leonard, Head of Operations


Thrive Bioscience, Inc.

Is developing Smart Incubation Systems™ that will automatically monitor, maintain, passage, and assay cell and tissue culture.

Alan Blanchard, CSO; Thomas Farb, COO/CFO; Brian Foley, VP of Engineering & Manufacturing



TriBiotica’s proprietary technology uses the tumor’s unique genetic signature to force the tumor cells to assemble novel immune targets that would not be naturally produced, but which allows specific elimination of tumor cells

Jim Kurnick, MD, Chairman; Matt Lawlor, President; Ian Dunn, CTO; Estelle Newton